BioSpace News Archive

Researchers at the University of California, San Diego (UCSD) ran successful animal studies of a gene therapy that appeared to cure a disease in mice similar to amyotrophic lateral sclerosis (ALS), sometimes also known as Lou Gehrig’s Disease.

Based in San Diego, Mirum entered into the agreement with Shire for the exclusive global rights to develop and market maralixibat, a Phase II oral inhibitor of the apical sodium-dependent bile acid transporter (ASBT).

Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.

Patent Infringement complaints around fractional RF micro-needling treatment systems filed against 18 manufacturers progresses

IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn devices, today announced that Mark Gorder, president and chief executive officer, will present at the Stifel 2018 Healthcare Conference at The Lotte New York Palace Hotel in New York City on Wednesday, Nov. 14, at approximately 11 a.m., ET.

Spinal Elements’ products featuring Ti-Bond’s complex macro-, micro- and nano-surface structure have been applied in tens of thousands of procedures since introduction in 2012

Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled

Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York City.

CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), today announced that management will be ringing the Nasdaq Stock Market Opening Bell on Thursday, November 8, 2018.

TransPerfect Life Sciences, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced that Symphogen has selected TransPerfect’s Trial Interactive eTMF and supporting TMF services to centralize and streamline operations for current and future studies.